1. Introduction {#s0005}
===============

The treatment of patients with Lafora disease (LD), a form of progressive myoclonus epilepsies (PME), proves to be very difficult, and previously healthy children or teenagers are afflicted with ever-worsening and soon-intractable myoclonus and epilepsy, which are usually associated with dementia and early death [@bb0005; @bb0010].

Lafora disease is an autosomal recessive, most commonly teenage-onset neurodegenerative disorder caused by mutations in either the *EPM2A* or *NHLRC1* gene, encoding the interacting proteins laforin and malin, respectively. Patients with LD usually present between 8 and 18 years of age with an insidious near-simultaneous or closely consecutive appearance of headaches, difficulties in school work, myoclonus, generalized tonic--clonic seizures (GTCS), and visual hallucinations of both epileptic and psychotic origin. For many years, patients struggle to maintain normal contact and communication, interrupted by extremely frequent myoclonic absence seizures. Gradually, dementia sets in, and patients are in an almost continuous myoclonus with absences, frequent GTCS, and profound dementia or vegetative state within a decade of onset [@bb0005; @bb0010; @bb0015].

We report a case in which perampanel was started in an adult patient with advanced LD leading to sustained remission in myoclonus and generalized tonic--clonic seizures.

2. Case report {#s0010}
==============

A 14-year-old, normally developed girl of Turkish descent initially presented to our clinic with myoclonus and GTCS. During video-EEG monitoring, interictal generalized spikes and polyspikes as well as three seizures with generalized onset were recorded. There was no evidence of focal EEG seizure onset. Over the next 7 years, no seizure remission had been achieved on various combinations of antiepileptic drugs or treatment with vagus nerve stimulation. Follow-up at the age of 18 years showed mild generalized and hippocampal atrophy on MRI ([Fig. 1](#f0005){ref-type="fig"}A--D). Neuropsychological evaluation showed a decline in language skills, especially in German, her second language. The patient spoke slowly and only few words with perseverations. Her attendance at a special school had decreased because of the seizures. No standardized neuropsychological testing was possible. The patient could name colors correctly and was interested in details of shown pictures. We observed a decline in language skills and attention, but motivational skills remained as a cognitive resource. Since then, disturbance in gait (ataxia) and cognitive decline were rapidly progressing, and eventually, the patient lost her ability to speak.

The suspected diagnosis of Lafora disease was confirmed by the identification of a novel homozygous missense mutation in exon 3 of the *EPM2A* gene (c.538C\>G; p.L180V) by Sanger sequencing, which was heterozygous in her unaffected parents.

In April 2012, the 21-year-old patient was admitted with a generalized convulsive status epilepticus (SE) that proved super-refractory [@bb0020]. Therapy with thiopental anesthesia, steroids, and magnesium did not control the SE, and a termination of all therapy was considered. Finally, initiation and maintenance of a ketogenic diet terminated the SE, as reported earlier [@bb0025], and the patient was discharged. She was bedbound and continued to suffer from daily myoclonus and frequent GTCS every 3--4 days despite antiepileptic polytherapy with high doses of valproate, levetiracetam, clonazepam, piracetam, and zonisamide and ketogenic diet.

Subsequently, the patient was admitted in September 2012 because of seizure exacerbation caused by infection and fluoroquinolone antibiotic therapy. The EEG showed generalized epileptiform discharges and frequent myoclonus ([Fig. 2](#f0010){ref-type="fig"}). The patient was started on an adjunctive therapy with the newly licensed perampanel, which was quickly titrated up to 8 mg/day within one week. No side effects were observed. The other anticonvulsant agents, such as valproate (1350 mg/day), levetiracetam (4000 mg/day), zonisamide (600 mg/day), clonazepam (12 mg/day), piracetam (12,000 mg/day), and the ketogenic diet (4:1 ratio) were not changed at this point in time. The GTCS stopped, and the patient was discharged. On follow-up four months later, the parents reported sustained seizure remission without myoclonus and GTCS for more than 3 months on an unchanged therapeutic regimen (see [Table 1](#t0005){ref-type="table"}). The EEG showed less epileptiform discharges ([Fig. 3](#f0015){ref-type="fig"}). The patient was able to walk with help and the aid of a walker and could climb a few stairs during physiotherapy. A few weeks later, the parents reported gait problems, and therefore, perampanel was decreased from 8 mg/day to 6 mg/day. Generalized tonic--clonic seizures recurred, but control was again achieved after increasing perampanel to 10 mg/day with a follow-up of another three months.

3. Discussion {#s0015}
=============

Perampanel was used off-label in this patient with advanced LD and resulted in a sustained and reproducible remission of myoclonus and GTCS. Transient dose reduction of perampanel caused the reoccurrence of seizures, proving the causal relationship of therapy with perampanel and seizure freedom in this progressive disorder.

Perampanel is a selective, noncompetitive antagonist of AMPA-type glutamate receptors and was recently licensed as adjunctive therapy for the treatment of refractory focal onset seizures [@bb0030; @bb0035; @bb0040]. Perampanel exhibited broad-spectrum efficacy in various animal seizure models, and there is evidence for its effectiveness in generalized epilepsies [@bb0045]. A phase 3 trial to determine the efficacy and safety of adjunctive perampanel in primary GTCS is currently recruiting patients (ClinicalTrials.gov identifier: [NCT01393743](ctgov:NCT01393743){#ir0010}). The reason for the striking efficacy in our patient with LD remains elusive and requires further study.

New treatment options are desired in PME such as LD and Unverricht--Lundborg disease [@bb0005; @bb0010] to improve daily functioning and seizure control. Our case illustrates that perampanel might be a valuable option for treatment in PME. Considering its impressive efficacy in this case, we suggest a prospective, multicenter study evaluating perampanel in PME.
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![T1, T2, and FLAIR MRI with mild generalized atrophy (A, B) as well as bilateral hippocampal atrophy (C, D).](gr1){#f0005}

![EEG with generalized epileptiform discharges and associated myoclonus before initiation of perampanel.](gr2){#f0010}

![EEG with bifrontal polyspikes and generalized slowing on follow-up.](gr3){#f0015}

###### 

Antiepileptic therapy and serum concentrations during seizure remission.

  Anticonvulsant   Daily dose   Serum concentration   Therapeutic level
  ---------------- ------------ --------------------- -------------------
  Clonazepam       12 mg        n.a.                  n.a.
  Levetiracetam    4000 mg      22.3 mg/l             3--34 mg/l
  Perampanel       8 mg         442 μg/l              100--800 μg/l
  Piracetam        12,000 mg    52 μg/ml              n.a.
  Valproate        1350 mg      69.8 μg/ml            40--100 μg/ml
  Zonisamide       600 mg       21.6 μg/ml            10--40 μg/ml
  Ketogenic diet   4:1 ratio                          
